Conferences - Results from #320

SUFU 2022: Incidence of Urinary Tract Infections Between Neurogenic and Non-Neurogenic Bladder Dysfunction Patients Performing Intermittent Catheterization - An Analysis of Marketscan Data March 1, 2022

ASCO GU 2022: First-Line Pembrolizumab with or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Study. February 25, 2022

ASCO GU 2022: Bladder-Sparing Trimodality Therapy: Toxicity and Functional Outcomes in the Era of Novel Therapeutics February 25, 2022

ASCO GU 2022: A Path Forward: Addressing Disparities in Genitourinary Cancers February 25, 2022

ASCO GU 2022: ABLE: Phase 2, Single-Arm, Two-Stage Study of Nab-Paclitaxel with Anti-PD1/PDL1 in Advanced Urothelial Cancer February 25, 2022

ASCO GU 2022: Biomarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy February 25, 2022

ASCO GU 2022: First-Line Pembrolizumab in Advanced Urothelial Carcinoma: Clinical Parameters Associated with Efficacy in the Phase 2 KEYNOTE-052 and Phase 3 KEYNOTE-361 Trials February 25, 2022

ASCO GU 2022: Impact of Primary Tumor Location on Efficacy and Safety of Pembrolizumab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Enrolled in the Phase 2 KEYNOTE-052 and Phase 3 KEYNOTE-045 Trials February 25, 2022

ASCO GU 2022: Futibatinib plus Pembrolizumab in Patients with Advanced or Metastatic Urothelial Carcinoma: Preliminary Safety Results from a Phase 2 Study February 25, 2022

ASCO GU 2022: Molecular Residual Disease Detection with a Tissue Comprehensive Genomic Profiling-Informed Personalized Monitoring Assay: An Exploratory Analysis of the IMvigor-010 Observation Arm February 24, 2022

ASCO GU 2022: Post Hoc Analysis of the Efficacy of Pembrolizumab Retreatment After Progression of Advanced Urothelial Carcinoma in KEYNOTE-045 and KEYNOTE-052 February 24, 2022

ASCO GU 2022: PD-L1 Expression and BCG Response in Nonmuscle Invasive Bladder Cancer (NMIBC) February 24, 2022

ASCO GU 2022: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab in Patients with Metastatic Urothelial Carcinoma (POLARIS-03 Study): Two-Year Survival Update and Biomarker Analysis February 24, 2022

ASCO GU 2022: Study RC48-C014: Preliminary Results of RC48-ADC Combined with Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma February 24, 2022

ASCO GU 2022: SWOG S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, MIBC with Overall Survival Follow Up February 24, 2022

ASCO GU 2022: The Association of FDG PET/CT and NaF PET/CT with Survival Outcomes in Patients with Metastatic Genitourinary Malignancies Treated with Cabozantinib + Nivolumab +/- Ipilimumab February 24, 2022

ASCO GU 2022: Treatment Outcomes for mCRPC Following Progression on Upfront ADT with Androgen Receptor Pathway Inhibitors for mCSPC February 24, 2022

ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib February 24, 2022

ASCO GU 2022: Real-World Health-Related Quality of Life and Caregiver Needs in Patients with mHSPC and mCRPC February 24, 2022

ASCO GU 2022: Real-World Analyses of Major Adverse Cardiovascular Event Risk by Drug Class After Initiation of ADT February 24, 2022

Page 17 of 465

email news signup